[CAS NO. 1195765-45-7] Dabrafenib (GSK2118436)
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1195765-45-7]
Store
Catalog
SLK-S2807
Brand
Selleck
CAS
1195765-45-7
DESCRIPTION [1195765-45-7]
Overview
| MDL | MFCD17215684 |
|---|---|
| Molecular Weight | 519.56 |
| Molecular Formula | C23H20F3N5O2S2 |
| SMILES | FC1=C(C2=C(SC(C(C)(C)C)=N2)C3=NC(N)=NC=C3)C=CC=C1NS(=O)(=O)C4=C(F)C=CC=C4F |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9247 mL | 9.6235 mL | 19.2471 mL |
| 5 mM | 0.3849 mL | 1.9247 mL | 3.8494 mL |
| 10 mM | 0.1925 mL | 0.9624 mL | 1.9247 mL |
| 50 mM | 0.0385 mL | 0.1925 mL | 0.3849 mL |
Description
Dabrafenib (GSK2118436, GSK2118436A) is a mutant specific inhibitor with of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.
Targets
In vitro
Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-Raf kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-Raf.
References
Synonyms
Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-
N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
Dabrafenib
GSK 2118436
Dabarefenib
Tafinlar
GSK 436
N-[3-[5-(2-Aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
Tafmlar
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.